Cited by 751Pharmacogenetics and Drug MetabolismCoffee research and impactsGenetic Associations and Epidemiology

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Functional significance of a C–>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine

Open access

Sachse, Christoph, Brockmöller, Jürgen, Bauer, Steffen, Roots, Ivar·1999·British Journal of Clinical Pharmacology

DOI 10.1046/j.1365-2125.1999.00898.xPMC PMC2014233

Open this paper in CoChat — free account Open PDF

Abstract

AIMS: The cytochrome P450 enzyme CYP1A2 metabolises several drugs and carcinogens. We wanted to determine how much of the variability of CYP1A2 activity is explained by a newly discovered gene polymorphism in intron 1. METHODS: A single nucleotide polymorphism in intron 1 of the CYP1A2 gene at position 734 downstream of the first transcribed nucleotide was identified by DNA sequence analysis. The functional significance of this C/A polymorphism was assessed in 185 healthy Caucasian non-smokers and in 51 smokers by genotyping and phenotyping using caffeine (100 mg oral dose). RESULTS: Out of the total sample, 46% were homozygous for the variant A, 44% were heterozygous, and 10% were homozygous for the variant C. The ratio of 1,7-dimethylxanthine (17X) plus 1,7-dimethyluric acid divided by caffeine in 0-5 h urine samples from 185 non-smokers did not differ significantly between the three CYP1A2 genotypes. In the 51 smokers, analysis of variance revealed significant differences in the 5 h plasma 17X/caffeine ratios between the genotypes (P=0.008, F-test). The mean ratio was 1.37 in carriers of the A/A genotype, 0.88 in heterozygotes and 0.82 in carriers of C/C. The mean difference between the A/A and C/A groups was 0.48 (95% confidence interval 0. 15-0.81; P=0.01). CONCLUSIONS: The A/A genotype, which may represent a CYP1A2 high inducibility genotype, may either be a direct cause of increased CYP1A2 activity, or be genetically linked to polymorphisms conferring high inducibility. Further studies are needed to define the role of this polymorphism on the pharmacokinetics of drugs metabolised by CYP1A2 and in the activation of carcinogens.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1046/j.1365-2125.1999.00898.x

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions
Bertz, R., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 754
Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites
Butler, M. A., Lang, N. P., Young, J. F., Caporaso, N. E., Vineis, P., Hayes, R. B., Teitel, C. H., Massengill, J., Lawsen, M. F., & Kadlubar, F. F. (1992) · Pharmacogenetics · doi:10.1097/00008571-199206000-00003 · Cited by 419
Nomenclature for human CYP2D6 alleles
Daly, A. K., Brockmöller, J., Broly, F., Eichelbaum, M. F., Evans, W. E., Gonzalez, F. J., Huang, J. D., Idle, J. R., Ingelman‐Sundberg, M., Ishizaki, T., et al. (1996) · Pharmacogenetics · doi:10.1097/00008571-199606000-00001 · Cited by 396
Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity
Eaton, D. L., Gallagher, E. P., Bammler, T. K., & Kunze, K. L. (1995) · Pharmacogenetics · doi:10.1097/00008571-199510000-00001 · Cited by 271
Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities
KALOW, W., & Tang, B.-K. (1991) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1991.176 · Cited by 264
A simple test for acetylator phenotype using caffeine.
Grant, D. M., Tang, B., & KALOW, W. (1984) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1984.tb02372.x · Cited by 212
Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva
Fuhr, U., & Rost, K. L. (1994) · Pharmacogenetics · doi:10.1097/00008571-199406000-00001 · Cited by 182
HumanCYP1A2: Sequence, Gene Structure, Comparison with the Mouse and Rat Orthologous Gene, and Differences in Liver1A2mRNA Expression
Ikeya, K., Jaiswal, A. K., Owens, R. A., Jones, J. E., Nebert, D. W., & Kimura, S. (1989) · Molecular Endocrinology · doi:10.1210/mend-3-9-1399 · Cited by 147
Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene.
Nakajima, M., Yokoi, T., Mizutani, M., Shin, S., Kadlubar, F. F., & Kamataki, T. (1994) · PubMed · Cited by 141
Increase of cytochrome P450IA2 activity by omeprazole: Evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin
Rost, K. L., Brösicke, H., Brockmöller, J., Scheffler, M., Helge, H., & Roots, I. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.126 · Cited by 132

Show all 16 references

Research works printed but not linked: 2

MacLeod SL, 1998, . The role of recently discovered genetic polymorphism in the regulation of the human CYP1A2 gene., Proceedings of the American Association for Cancer Research, 39, 396
SambrookJ FritschEF ManiatisTMolecular cloning: a laboratory manual 2nd ed. Cold Spring Harbor Laboratory Press Cold Spring Harbor 1989

Sorted by citations

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
Genome-wide association study identifies eight loci associated with blood pressure
Wellcome Trust Case Control Consortium, Newton-Cheh, C., Johnson, T., Gateva, V., Tobin, M. D., Bochud, M., Coin, L., Najjar, S. S., Zhao, J. H., Heath, S. C., et al. (2009) · Nature Genetics · doi:10.1038/ng.361 · Cited by 1,215
Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects
Ingelman‐Sundberg, M., Sim, S. C., Gomez, A. V., & Rodríguez‐Antona, C. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.004 · Cited by 1,180
Coffee and Health: A Review of Recent Human Research
Higdon, J. V., & Frei, B. (2006) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408390500400009 · Cited by 1,090
Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders
(2000) · doi:10.1002/1520-6394(2000)12:1+
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S., Liu, J., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 857
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response
Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.-L., Licinio, J., Roots, I., & Brockmöller, J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001494 · Cited by 728
Interindividual Differences in Caffeine Metabolism and Factors Driving Caffeine Consumption
Nehlig, A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014407 · Cited by 632
Scientific Opinion on the safety of caffeine
EFSA Panel on Dietetic Products, N. A. A. (. (2015) · EFSA Journal · doi:10.2903/j.efsa.2015.4102 · Cited by 613
“A single base change of A to C at position 734 within intron 1 of the CYP1A2 gene decreases inducibility of the enzyme (Sachse et al., 1999; Han et al., 2001).”
Background
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
Zanger, U. M., Turpeinen, M., Klein, K., & Schwab, M. G. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2291-6 · Cited by 593
Cytochrome P450 pharmacogenetics and cancer
Rodríguez‐Antona, C., & Ingelman‐Sundberg, M. (2006) · Oncogene · doi:10.1038/sj.onc.1209377 · Cited by 574
Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers.
Bartsch, H., Nair, U., Risch, A., Rojas, M., Wikman, H., & Alexandrov, K. (2000) · PubMed · Cited by 569
Inhibition and induction of human cytochrome P450 enzymes: current status
Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., & Raunio, H. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0332-8 · Cited by 571
The Safety of Ingested Caffeine: A Comprehensive Review
Temple, J. L., Bernard, C., Lipshultz, S. E., Czachor, J. D., Westphal, J. A., & Mestre, M. A. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00080 · Cited by 557
Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment
Ingelman‐Sundberg, M., Oscarson, M., & McLellan, R. A. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01363-2 · Cited by 539
Coffee, caffeine, and sleep: a systematic review of epidemiological studies and randomized controlled trials
Clark, I., & Landolt, H. P. (2017) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2016.01.006 · Cited by 499
Coffee, CYP1A2 genotype, and risk of myocardial infarction
Cornelis, M. C., El-Sohemy, A., Kabagambe, E. K., & Campos, H. (2006) · JAMA · doi:10.1001/jama.295.10.1135 · Cited by 490
Population genetic structure of variable drug response
Wilson, J. F., Weale, M. E., Smith, A. C., Gratrix, F., Fletcher, B., Thomas, M., Bradman, N. N., & Goldstein, D. B. (2001) · Nature Genetics · doi:10.1038/ng761 · Cited by 460
Applications of CYP450 Testing in the Clinical Setting
Samer, C. F., Lorenzini, K. I., Rollason, V., Daali, Y., & Desmeules, J. A. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0028-5 · Cited by 355
Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research
Arranz, M. J., & de León, J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002009 · Cited by 355
Efficacy of Acute Caffeine Ingestion for Short-term High-Intensity Exercise Performance: A Systematic Review
Astorino, T., & Roberson, D. W. (2010) · Journal of Strength and Conditioning Research · doi:10.1519/jsc.0b013e3181c1f88a · Cited by 335
Genetics of caffeine consumption and responses to caffeine
Yang, A., Palmer, A. A., & de Wit, H. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1900-1 · Cited by 330
Assessment of CYP1A2 Activity in Clinical Practice: Why, How, and When?
Faber, M. S., Jetter, A., & Fuhr, U. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_973160.x · Cited by 284
Cytochrome P450 variations in different ethnic populations
McGraw, J. E., & Waller, D. P. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.657626 · Cited by 284
A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer
Sachse, C. (2002) · Carcinogenesis · doi:10.1093/carcin/23.11.1839 · Cited by 284
Influence of Dose, Cigarette Smoking, Age, Sex, and Metabolic Activity on Plasma Clozapine Concentrations
Rostami‐Hodjegan, A., Amin, A. M., Spencer, E. P., Lennard, M. S., Tucker, G. T., & Flanagan, R. J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000106221.36344.4d · Cited by 279
Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans
Ghotbi, R., Christensen, M., Roh, H., Ingelman‐Sundberg, M., Aklillu, E., & Bertilsson, L. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0288-2 · Cited by 265
Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2
Zhou, S.-F., Wang, B., Yang, L.-P., & Liu, J. (2009) · Drug Metabolism Reviews · doi:10.3109/03602530903286476 · Cited by 270
The Effect of Acute Caffeine Ingestion on Endurance Performance: A Systematic Review and Meta–Analysis
Southward, K., Rutherfurd-Markwick, K. J., & Ali, A. (2018) · Sports Medicine · doi:10.1007/s40279-018-0939-8 · Cited by 254
Variation in CYP1A2 Activity and its Clinical Implications: Influence of Environmental Factors and Genetic Polymorphisms
Gunes, A., & Dahl, M. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.5.625 · Cited by 257
Smoking in Patients Receiving Psychotropic Medications: A Pharmacokinetic Perspective
Desai, H. D., Seabolt, J., & Jann, M. W. (2001) · CNS Drugs · doi:10.2165/00023210-200115060-00005 · Cited by 253
Time response of cytochrome P450 1A2 activity on cessation of heavy smoking*1
Faber, M. S. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.04.003 · Cited by 251
ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment
Crettol, S., Déglon, J., BESSON, J., Croquette-Krokar, M., Hämmig, R., Gothuey, I., Monnat, M., & Eap, C. B. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.012 · Cited by 249
The interindividual differences in the 3‐demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors
Rasmussen (2002) · Pharmacogenetics · doi:10.1097/00008571-200208000-00008 · Cited by 241
Insights into the Substrate Specificity, Inhibitors, Regulation, and Polymorphisms and the Clinical Impact of Human Cytochrome P450 1A2
Zhou, S. F., Yang, L.-P., Zhou, Z.-W., Liu, Y., & Chan, E. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9127-y · Cited by 239
Genetic polymorphism of the adenosine A2A receptor is associated with habitual caffeine consumption
Cornelis, M. C., El‐Sohemy, A., & Campos, H. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.1.240 · Cited by 231
CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension
Palatini, P., Ceolotto, G., Ragazzo, F., Dorigatti, F., Saladini, F., Papparella, I., Mos, L., Zanata, G., & Santonastaso, M. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e32832ba850 · Cited by 230
Caffeine Consumption through Coffee: Content in the Beverage, Metabolism, Health Benefits and Risks
DePaula, J., & Farah, A. (2019) · Beverages · doi:10.3390/beverages5020037 · Cited by 258
Cytochrome P450: Polymorphisms and Roles in Cancer, Diabetes and Atherosclerosis
Elfaki, I., Mir, R., Almutairi, F. M., & Abuduhier, F. M. (2018) · Europe PMC (PubMed Central) · doi:10.22034/apjcp.2018.19.8.2057 · Cited by 218
Are the Current Guidelines on Caffeine Use in Sport Optimal for Everyone? Inter-individual Variation in Caffeine Ergogenicity, and a Move Towards Personalised Sports Nutrition
Pickering, C., & Kiely, J. (2017) · Sports Medicine · doi:10.1007/s40279-017-0776-1 · Cited by 228
Brassica, Biotransformation and Cancer Risk: Genetic Polymorphisms Alter the Preventive Effects of Cruciferous Vegetables
Lampe, J. W., & Trudo, S. P. (2002) · Journal of Nutrition · doi:10.1093/jn/131.10.2991 · Cited by 203
Genetic Polymorphism of Metabolic Enzymes P450 (CYP) as a Susceptibility Factor for Drug Response, Toxicity, and Cancer Risk
Božina, N., Bradamante, V., & Lovrić, M. (2009) · Archives of Industrial Hygiene and Toxicology · doi:10.2478/10004-1254-60-2009-1885 · Cited by 201
Sex-specific differences in CYP450 isoforms in humans
Scandlyn, M. J., Stuart, E. C., & Rosengren, R. J. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.4.413 · Cited by 199
Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function
Stingl, J., Brockmöller, J., & Viviani, R. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.42 · Cited by 200
Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction
Zhang, J., & Malhotra, A. K. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.532787 · Cited by 194
Pharmacogenetics of oral anticoagulants
Daly, A. K., & King, B. P. (2003) · Pharmacogenetics · doi:10.1097/00008571-200305000-00002 · Cited by 195
A Highly Selective Ratiometric Two-Photon Fluorescent Probe for Human Cytochrome P450 1A
Dai, Z., Ge, G., Feng, L., Ning, J., Hu, L., Jin, Q., Wang, D., Lv, X., Dou, T., Cui, J., et al. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b09854 · Cited by 194
Pharmacogenetics of the major polymorphic metabolizing enzymes
Daly, A. K. (2003) · Fundamental and Clinical Pharmacology · doi:10.1046/j.1472-8206.2003.00119.x · Cited by 189
Caffeine as a factor influencing the functioning of the human body-friend or foe?
Rodak, K., Kokot, I., & Kratz, E. M. (2021) · Nutrients · doi:10.3390/nu13093088 · Cited by 188
Cytochrome P450 in Pharmacogenetics: An Update
Tornio, A., & Backman, J. T. (2018) · Advances in pharmacology · doi:10.1016/bs.apha.2018.04.007 · Cited by 182
Genetic Polymorphism of CYP1A2 in Ethiopians Affecting Induction and Expression: Characterization of Novel Haplotypes with Single-Nucleotide Polymorphisms in Intron 1
Aklillu, E., Carrillo, J. A., Makonnen, E., Hellman, K., Pitarque, M., Bertilsson, L., & Ingelman‐Sundberg, M. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.3.659 · Cited by 181
Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases
Zordoky, B. N. M., & El‐Kadi, A. O. S. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.12.002 · Cited by 179
The influence of a CYP1A2 polymorphism on the ergogenic effects of caffeine
Womack, C. J., Saunders, M. J., Bechtel, M. K., Bolton, D. J., Martin, M., Luden, N. D., Dunham, W., & Hancock, M. (2012) · Journal of the International Society of Sports Nutrition · doi:10.1186/1550-2783-9-7 · Cited by 178
The effect of variable cigarette consumption on the interaction with clozapine and olanzapine
Haslemo, T., Eikeseth, P. H., Tanum, L., Molden, E., & Refsum, H. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0209-9 · Cited by 178
Role of the Smoking-Induced Cytochrome P450 (CYP)1A2 and Polymorphic CYP2D6 in Steady-State Concentration of Olanzapine
Carrillo, J. A., Herráiz, A. G., Ramos, S., Gervasini, G., Vizcaíno, S., & Benítez, J. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200304000-00003 · Cited by 180
The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement
van der Weide, J., Steijns, L. S. W., & van Weelden, M. J. M. (2003) · Pharmacogenetics · doi:10.1097/00008571-200303000-00006 · Cited by 176
Inter‐individual variability in levels of human microsomal protein and hepatocellularity per gram of liver
Wilson, Z., Rostami‐Hodjegan, A., Burn, J. L., Tooley, A., Boyle, J., Ellis, S. W., & Tucker, G. T. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01881.x · Cited by 175
Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism
Sachse, C., Bhambra, U., Smith, G. C., Lightfoot, T. J., Barrett, J. H., Scollay, J., Garner, R. C., Boobis, A. R., Wolf, C. R., Gooderham, N. J., et al. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01733.x · Cited by 173
Caffeine and Exercise: What Next?
Pickering, C., & Grgić, J. (2019) · Sports Medicine · doi:10.1007/s40279-019-01101-0 · Cited by 195
Caffeine Metabolism, Genetics, and Perinatal Outcomes: A Review of Exposure Assessment Considerations during Pregnancy
Grosso, L. M., & Bracken, M. B. (2005) · Annals of Epidemiology · doi:10.1016/j.annepidem.2004.12.011 · Cited by 170
Genetic susceptibility to adverse effects of drugs and environmental toxicants
Ingelman‐Sundberg, M. (2001) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(01)00205-6 · Cited by 170
A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia
Basile, V. S., Özdemir, V., Masellis, M., Walker, M. L., Meltzer, H. Y., Lieberman, J. A., Potkin, S. G., Alva, G., KALOW, W., Macciardi, F. M., et al. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000736 · Cited by 168
Cytochrome P450 Phenotyping/Genotyping in Patients Receiving Antipsychotics
Dahl, M. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241070-00001 · Cited by 163
Pharmacogenetics-based therapeutic recommendations — ready for clinical practice?
Kirchheiner, J., Fuhr, U., & Brockmöller, J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1801 · Cited by 163
Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism.
Goodman, M. T., McDuffie, K., Kolonel, L. N., Terada, K. Y., Donlon, T. A., Wilkens, L. R., Guo, C., & Marchand, L. L. (2001) · PubMed · Cited by 157
Cytochrome P450 enzyme polymorphisms and adverse drug reactions
Pirmohamed, M., & Park, B. K. (2003) · Toxicology · doi:10.1016/s0300-483x(03)00247-6 · Cited by 152
The role of genetic polymorphisms in environmental health.
Kelada, S. N., Eaton, D. L., WANG, S. S., Rothman, N., & Khoury, M. J. (2003) · Environmental Health Perspectives · doi:10.1289/ehp.6065 · Cited by 150
A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer
Landi, S., Gemignani, F., Moreno, V. R., Gioia‐Patricola, L., Chabrier, A., Guinó, E., Navarro, M., de, J., Capellá, G., & Canzian, F. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000165904.48994.3d · Cited by 148
ABCB1 and Cytochrome P450 Polymorphisms
Sirot, E. J., Knežević, B., Morena, P., Harenberg, S., Oneda, B., Crettol, S., Ansermot, N., Baumann, P., & Eap, C. B. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181acc372 · Cited by 148
Dietary Phytoestrogen Intake Is Associated with Reduced Colorectal Cancer Risk
Cotterchio, M., Boucher, B. A., Manno, M., Gallinger, S., Okey, A. B., & Harper, P. A. (2006) · Journal of Nutrition · doi:10.1093/jn/136.12.3046 · Cited by 150
Clinical applications of CYP genotyping in psychiatry
Spina, E., & de León, J. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1300-5 · Cited by 146
Sequence variants at CYP1A1–CYP1A2 and AHR associate with coffee consumption
Sulem, P., Gudbjartsson, D. F., Geller, F., Prokopenko, I., Feenstra, B., Aben, K. K. H., Franke, B., den Heijer, M., Kovacs, P. L., Stümvoll, M., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr086 · Cited by 144
Role of the aryl hydrocarbon receptor in drug metabolism
Ramadoss, P., Marcus, C. B., & Perdew, G. H. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.1.9 · Cited by 147
Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions
Bakker, P. R., van Harten, P. N., & van Os, J. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002142 · Cited by 143
PharmGKB summary
Thorn, C. F., Aklillu, E., Klein, T. E., & Altman, R. B. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834c6efd · Cited by 141
Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM
kConFab Investigators, Amin, N., Byrne, E. M., Johnson, J., Chenevix‐Trench, G., Walter, S., Nolte, I. M., Vink, J. M., Rawal, R., Mangino, M., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.101 · Cited by 139
Strategies and Molecular Probes to Investigate the Role of Cytochrome P450 in Drug Metabolism
Donato, M. T., & Castell, J. V. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342020-00004 · Cited by 138
Phenotypic polymorphism and gender‐related differences of CYP1A2 activity in a Chinese population
Ou‐Yang, D., Huang, S., Wang, W., Xie, H., Xu, Z., Shu, Y., & Zhou, H. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00128.x · Cited by 133
Metabolic activation of carcinogens and expression of various cytochromes P450 in human prostate tissue
Williams, J. A., Martin, F. L., Muir, G., Hewer, A. J., Grover, P. L., & Phillips, D. H. (2000) · Carcinogenesis · doi:10.1093/carcin/21.9.1683 · Cited by 128
What Should We Do about Habitual Caffeine Use in Athletes?
Pickering, C., & Kiely, J. (2019) · Sports Medicine · doi:10.1007/s40279-018-0980-7 · Cited by 127
Precision (Personalized) Nutrition: Understanding Metabolic Heterogeneity
Zeisel, S. H. (2020) · Annual Review of Food Science and Technology · doi:10.1146/annurev-food-032519-051736 · Cited by 135
Nonresponse to Clozapine and Ultrarapid CYP1A2 Activity
Eap, C. B., Bender, S., Sirot, E. J., Cucchia, G., Jonzier-Perey, M., Baumann, P., Allorge, D., & Broly, F. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000116646.91923.2f · Cited by 125
Organization of the CYP1A cluster on human chromosome 15: implications for gene regulation
Corchero, J., Pimprale, S., Kimura, S., & Gonzalez, F. J. (2001) · Pharmacogenetics · doi:10.1097/00008571-200102000-00001 · Cited by 125
Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents
Murray, M. T. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.7.0001 · Cited by 124
Pharmacogenomics in schizophrenia: the quest for individualized therapy
Basile, V. S. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.20.2517 · Cited by 124
Effects of red bull energy drink on repeated sprint performance in women athletes
Astorino, T. A., Matera, A. J., Basinger, J., Evans, M., Schurman, T., & Marquez, R. (2011) · Amino Acids · doi:10.1007/s00726-011-0900-8 · Cited by 120
Long-term coffee consumption, caffeine metabolism genetics, and risk of cardiovascular disease: a prospective analysis of up to 347,077 individuals and 8368 cases
Zhou, A., & Hyppönen, E. (2018) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqy297 · Cited by 125
Pharmacogenetics
Ensom, M. H. H., Chang, T. K. H., & Patel, P. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140110-00001 · Cited by 119
Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson’s disease
Popat, R. A., Eeden, S. K. V. D., Tanner, C. M., Kamel, F., Umbach, D. M., Marder, K. S., Mayeux, R. P., Ritz, B. R., Ross, G. W., Petrovitch, H., et al. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03353.x · Cited by 119
Estrogen Metabolism–Related Genes and Breast Cancer Risk: The Multiethnic Cohort Study
Marchand, L. L., Donlon, T. A., Kolonel, L. N., Henderson, B. E., & Wilkens, L. R. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0076 · Cited by 118
Detection of Three Genetic Polymorphisms in the 5′‐Flanking Region and Intron 1 of Human CYP1A2 in the Japanese Population
Chida, M., Yokoi, T., Fukui, T., Kinoshita, M., Yokota, J., & Kamataki, T. (1999) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1999.tb00832.x · Cited by 118
Impact of Smoking, Smoking Cessation, and Genetic Polymorphisms on CYP1A2 Activity and Inducibility
Dobrinas, M., Cornuz, J., Oneda, B., Serra, M. K., Puhl, M., & Eap, C. B. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.70 · Cited by 117
Pharmacogenetics of antidepressants
Crisafulli, C., Fabbri, C., Porcelli, S., Drago, A., Spina, E., De Ronchi, D., & Serretti, A. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00006 · Cited by 113
Coffee, caffeine, and coronary heart disease
Cornelis, M. C., & El‐Sohemy, A. (2007) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e3282f05d81 · Cited by 113
A review of the epidemiologic evidence concerning the reproductive health effects of caffeine consumption: A 2000–2009 update
Peck, J. D., Leviton, A., & Cowan, L. D. (2010) · Food and Chemical Toxicology · doi:10.1016/j.fct.2010.06.019 · Cited by 111
Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women
Sangrajrang, S., Sato, Y., Sakamoto, H., Ohnami, S., Laird, N. M., Khuhaprema, T., Brennan, P., Boffetta, P., & Yoshida, T. (2009) · International Journal of Cancer · doi:10.1002/ijc.24434 · Cited by 112
Therapeutic Drug Monitoring and Pharmacogenetic Tests as Tools in Pharmacovigilance
Sirot, E. J., van der Velden, J. W., Rentsch, K., Eap, C. B., & Baumann, P. (2006) · Drug Safety · doi:10.2165/00002018-200629090-00001 · Cited by 112
Biological roles of cytochrome P450 1A1, 1A2, and 1B1 enzymes
Kwon, Y., Shin, S., & Chun, Y. (2021) · Archives of Pharmacal Research · doi:10.1007/s12272-021-01306-w · Cited by 112
Genetic polymorphisms in heterocyclic amine metabolism and risk of colorectal adenomas
Ishibe, N., Sinha, R. R., Hein, D. W., Kulldorff, M., Strickland, P. T., Fretland, A. J., Chow, W., Kadlubar, F. F., Lang, N. P., & Rothman, N. (2002) · Pharmacogenetics · doi:10.1097/00008571-200203000-00008 · Cited by 111
Pharmacogenetics of Warfarin
Kamali, F., & Wynne, H. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.070808.170037 · Cited by 109

Authors: Sachse, C., Brockmöller, J., Bauer, S., & Roots, I.
Affiliations: Humboldt-Universität zu Berlin (DE)
ORCID: Sachse, Christoph
Brockmöller, Jürgen
Venue: British Journal of Clinical Pharmacology
Publisher: Wiley
Published: 1999-04
Volume: 47
Issue: 4
Pages: 445-449
ISSN: 0306-5251 (ISSN-L)
1365-2125
DOI: 10.1046/j.1365-2125.1999.00898.x
PMC: PMC2014233
OpenAlex: W1734451748
Cited by: 751
References: 16
Citations by year: 2026: 12 · 2025: 21 · 2024: 27 · 2023: 27 · 2022: 18 · 2021: 21 · 2020: 39 · 2019: 17 · 2018: 30 · 2017: 20 · 2016: 31 · 2015: 27 · 2014: 27 · 2013: 26 · 2012: 42
FWCI: 19.35
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 998 d)
Locations: British Journal of Clinical Pharmacology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Health Sciences › Medicine › Pharmacology (medical) › Coffee research and impacts
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords: CYP1A2, cytochrome P450, intron 1 polymorphism, caffeine, 1,7-dimethylxanthine, enzyme inducibility, smokers, genetic variation in drug metabolism, pharmacogenetics, carcinogen activation
MeSH terms: Caffeine, Humans, Introns, Polymorphism, Genetic, Smoking, Cytochrome P-450 CYP1A2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Functional significance of a C–>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks